Previous 10 | Next 10 |
Point Biopharma Global's ( NASDAQ: PNT ) stock fell ~35% on Monday after the company said it was selling licensing rights to radiopharmaceutical cancer drug candidates PNT2002 and PNT2003 to Lantheus ( NASDAQ: LNTH ). Upon completion, Lantheus ...
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticals Expands Lantheus’ portfolio with license of exclusive worldwide rights, excluding cer...
NORTH BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc . (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find,...
Lantheus Holdings, Inc. (LNTH) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Mark Kinarney - VP, IR Mary Heino - President and CEO Paul Blanchfield – COO Robert Marshall - CFO and Treasurer Conference Call Part...
Lantheus Holdings ( NASDAQ: LNTH ) dropped ~8% in the morning hours Thursday to reach the lowest level since July, even after the diagnostic compound maker announced better-than-expected Q3 2022 financials and set its outlook ahead of the consensus. Lantheus ( LNTH...
Lantheus press release ( NASDAQ: LNTH ): Q3 Non-GAAP EPS of $0.99 beats by $0.16 . Revenue of $239.29M (+134.4% Y/Y) beats by $11.41M . Net cash provided by operating activities was $93.6 million for the third quarter 2022. Free cash flow was $87.5 million in t...
Worldwide revenue of $239.3 million for the third quarter 2022, representing an increase of 134.4% from the prior year period GAAP net income of $61.2 million for the third quarter 2022, compared to GAAP net loss of $13.4 million in the prior year period GAAP fully dilut...
Lantheus ( NASDAQ: LNTH ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is $0.83 (+1137.5% Y/Y) and the consensus Revenue Estimate is $227.88M (+123.3% Y/Y). Over the last 2 years, LNTH has beat...
NORTH BILLERICA, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022, to discuss its financial and operating results fo...
NORTH BILLERICA, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow dis...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acqu...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...